对老年人过度活跃膀的口服药物的比较评估:系统性审查和网络元分析
Wenjuan He1, Chunyu Wang2, Bokun Chen2
1The Second Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
概括
化 (TRO) 是最有效的降低尿动频率在老年患者过度活动的膀 (OAB). 然而,vibegron (VIB) 和mirabegron (MIR) 提供了更好的安全性,并减少了口腔干燥和便秘等副作用.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 过度活跃的膀 (OAB) 显著影响老年人的生活质量.
- 目前对OAB的药理疗法在疗效和安全性方面有所不同,需要进行系统的比较.
研究的目的:
- 在老年人群中系统地比较各种药物的疗效和安全性,用于治疗过活性膀 (OAB).
- 根据OAB药物在减少排尿的有效性及其安全性资料来对OAB药物进行排名.
主要方法:
- 在主要数据库 (PubMed,Embase,Web of Science,Cochrane) 进行了系统的文献搜索,截至2023年7月25日.
- 针对老年人OAB治疗的随机,受控,双盲试验 (RCT) 被纳入并使用Stata17.0.0进行分析.
主要成果:
- 化 (TRO) 显示在减少流方面具有最高的有效性. 与安慰剂相比,托尔特罗丁ER (TOL) 没有显著差异.
- 托尔特罗丁ER (TOL) 呈现了治疗出现不良事件 (TEAE) 的最高发病率. 米拉贝格伦 (MIR),维贝格伦 (VIB) 和费索特罗丁 (FES) 4mg在口腔干燥和便秘方面耐受良好.
- 头痛的风险增加了TOL 4mg,FES 4/8mg和VIB. 使用FES 4/8mg和MIR 25mg时,头风险增加.
结论:
- 虽然TRO 60mg有效降低尿动频率,但与口腔干燥和便秘的增加有关.
- 维贝格龙 (VIB) 和米拉贝格龙 (MIR) 对口腔干燥和便秘具有良好的安全性,但可能会带来头痛或头的风险.
相关概念视频
Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
Cholinergic Antagonists: Pharmacokinetics
871
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
871
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
214
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
214
Urodynamic Studies: Uroflowmetry
2.9K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
2.9K
Drugs for Treatment of Diarrhea-Predominant IBS
590
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
590


